ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NVO vs ABT // GROSS PROFIT MARGIN

Novo Nordisk A/S (NYSE) VS. Abbott Laboratories (NYSE) • 15-METRIC TALLY: NVO 0 — ABT 13
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVO VS. ABT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NVO ABT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 56.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 11.90% -2.00 ABT /roic <GO>
EV/EBITDA & P/E Valuation 21.0x 18.4x +2.60 ABT /valuation <GO>
Free Cash Flow Yield 2.21% 4.09% -1.88 ABT /fcf-yield <GO>
Operating Margin 13.90% 18.20% -4.30 ABT /operating-margins <GO>
Net Profit Margin 10.90% 14.70% -3.80 ABT /net-margins <GO>
Revenue Growth (YoY) 2.20% 5.70% -3.50 ABT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABT /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 4.36 -0.62 ABT /balance-sheet <GO>
Piotroski F-Score Quality 7/9 8/9 -1.00 ABT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.9 54.2 -6.30 ABT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.87 0.99 -0.12 ABT /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 25.8x +4.70 ABT /forward-pe <GO>
Enterprise Scale & Market Cap $173.31B $180.95B -$7.64B ABT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NVO REV ABT REV NVO GROSS % ABT GROSS % NVO FCF ABT FCF
FY 2025 — $44.33B — 56.4% — $7.39B
FY 2024 — $41.95B — 55.4% — $6.35B
FY 2023 — $40.11B — — — $5.46B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVO // BETA 0.87
ABT // BETA 0.99